Gilead Sciences, Inc. $GILD Stock Holdings Increased by Ranch Capital Advisors Inc.

Ranch Capital Advisors Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 22,365 shares of the biopharmaceutical company’s stock after buying an additional 1,323 shares during the period. Gilead Sciences accounts for 1.1% of Ranch Capital Advisors Inc.’s portfolio, making the stock its 29th largest holding. Ranch Capital Advisors Inc.’s holdings in Gilead Sciences were worth $2,480,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $25,000. Activest Wealth Management increased its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences in the second quarter worth approximately $27,000. Goodman Advisory Group LLC acquired a new position in Gilead Sciences in the first quarter worth approximately $29,000. Finally, Colonial Trust Advisors increased its holdings in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Cantor Fitzgerald increased their price target on Gilead Sciences from $129.00 to $135.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Finally, Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.61.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,500 shares of company stock valued at $8,281,540. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Trading Up 0.2%

Shares of Gilead Sciences stock opened at $120.94 on Friday. The company has a market cap of $150.06 billion, a price-to-earnings ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company’s fifty day simple moving average is $115.47 and its 200-day simple moving average is $111.01. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.